News and Events

Sanovas Remarks on "How Crowdfunding Affects the Healthcare Market, and Your Wallet"

Crowdfunding is a significant and meaningful opportunity for emerging Life Science companies and individual investors, alike. America’s greatest asset has always been its people. The US was built upon microfunding. People doing business with people is the premise that resides at the very core of Capitalist ideals. This legislation beacons a return to civics and to personal enterprise. To remain at the leading edge of both innovation and prosperity Americans have to take control of our individual and collective destiny. This legislation presents an opportunity to regain the trust and camaraderie among citizens and corporations in restoring those capitalist ideals. With social media as the driver, communities and industries can invest in their collective interest.

The Life Science community is especially well suited to answer this call. Those endeavored in emerging Life Sciences are, on the whole, inherently well educated, well intentioned, highly professional and highly credible. These trust factors align emerging Life Science companies with the inspiration of an investing public. Nothing is more meaningful to an investor or the founder of a Life Science company than the opportunity to ‘Do Well by Doing Good’. Sentimentally, Crowdfunding presents the entrepreneur with an incredibly meaningful socioeconomic mandate. It is one thing to grow shareholder value on behalf of some perceivably ruthless institutional investor. It is an especially meaningful mandate to be entrusted to steward the hard-earned dollars of a cancer victim. There is no bigger motivation than to look an individual who is in peril in his eye with assurance, to pledge responsibility for his hopes and aspirations, and to consecrate his dying wish with a handshake.

The reward for success and the consequence for failure are both deeply personal and carry tremendous weight. A perfectly fitting inspiration from which to incent innovation. Only in Life Science!

Sanovas Interviewed on KGO 810 News

Larry Gerrans interviewed on KGO 810 News


      Click to play interview

            Larry Gerrans joined KGO 810 News for
            an interview about Sanovas. Click above
            to listen or read the transcription below.






Announcer: KGO; San Francisco, Oakland, San Jose, it's 6 o'clock.

Chris Brecher: 6:01 at KGO this is the afternoon news, I'm Chris Brecher, Nikki Medoro in for Bret Burkhart.

Well, there is new hope today, well, maybe not exactly today but soon for treating lung cancer and possibly other diseases as well thanks to a Bay Area company called Sanovas. They have invented a line of microsurgical tools that allow doctors to see places they have never seen before.

These tools might even allow them to feel the textures inside your lungs. To find out more about what these tools are and what they can do we turn to Larry Gerrans, he's the CEO and co-founder of Sanovas which is located in Sausalito by the way. He joins us on the KGO live line.

Describe your invention to us. What's it look like, how does it work?

Larry Gerrans: Sure. Sanovas' technologies are simply the next evolution of advance in the miniaturization of technologies sufficient to reach places and spaces and small diameter anatomy that here before have not been able to be accessed. And so we put together a tool belt of tools, so to speak, for doctors to access these places and to image them to diagnose the pathology that resides there and then to remove that pathology and then deliver drugs and immune therapies and the next generation of immunotherapy's to those tumors that reside in and around those airways.

Chris Brecher: Now, you've invented the Smart Catheter. Why do you call it that? What makes it so smart?

Larry Gerrans: Well historically you know catheters have been simple inflation devices or access devices and so one of the things that we came across was that many technology companies have failed for no fault of their own and despite their best intentions because they lack the intelligence and understanding of the anatomy that they're operating on because they're in such small, tight places.

So what we developed was a physiologic intelligence device called PHYSIOSENSE which allows us to effectively go into a small diameter anatomy and provide the physician with spatial dimensions and physiologic analytics is what we call them so that they can discern the density of, say, an obstruction, they can determine the module of elasticity of the vessel wall so they understand how much concentric force or linear translation that they would be able to exert in that airway or within that vessel so as not to damage the vessel inadvertently.

Chris Brecher: Now, what kind of diseases or conditions might this be used with, against?

Larry Gerrans: Certainly. Well, our current inspiration is lung cancer simply because one in seven Americans are currently afflicted with a pulmonary disease of which lung cancer is part of that cohort.

But we have broad application across the tubular anatomy so effectively we're proud of the fact that the portfolio of technologies can be used whether there's a small tubular anatomy; so for cardiovascular diseases, for neurologic diseases, neurology, for gynecologic drug delivery, gastrointestinal diseases, general surgeries and pancreatic cancer.

So, it's exciting.

Chris Brecher: It sure is. We've been talking with Larry Gerrans, he's the co-founder of the company that makes this wonderful invention, Sanovas, based in Sausalito. The catheter, as they call it, is also disposable so there's no chance of passing infections from one patient to another.

Sanovas Inc. is an emerging technology company. These products are investigational medical devices that have not been approved or cleared for use in the United States.